Disposition of 1855 shares by Michael Benkowitz of United Therapeutics at 401.6542 subject to Rule 16b-3
| UTHR Stock | USD 378.13 1.13 0.30% |
Slightly above 54% of United Therapeutics' investor base is interested to short. The analysis of overall sentiment of trading United Therapeutics stock suggests that many investors are impartial at this time. United Therapeutics' investing sentiment overview a quick insight into current market opportunities from investing in United Therapeutics. Many technical investors use United Therapeutics stock news signals to limit their universe of possible portfolio assets and to time the market correctly.
United |
Filed transaction by United Therapeutics Officer: President And Coo. Disposition to the issuer of issuer equity securities pursuant to Rule 16b-3(e)
Read at gurufocus.com
 |
United Therapeutics Fundamental Analysis
We analyze United Therapeutics' financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of United Therapeutics using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of United Therapeutics based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Net Income
Net Income Comparative Analysis
United Therapeutics is currently under evaluation in net income category among its peers. Net income is the profit of a company for the reporting period, which is derived after taking revenues and gains and subtracting all expenses and losses. Net income is one of the most-watched numbers by money managers as well as individual investors.
United Therapeutics Potential Pair-trading
One of the popular trading techniques among algorithmic traders is to use market-neutral strategies where every trade hedges away some risk. Because there are two separate transactions required, even if one position performs unexpectedly, the other equity can make up some of the losses. Below are some of the equities that can be combined with United Therapeutics stock to make a market-neutral strategy. Peer analysis of United Therapeutics could also be used in its relative valuation, which is a method of valuing United Therapeutics by comparing valuation metrics with similar companies.
Peers
United Therapeutics Related Equities
| LRMR | Larimar Therapeutics | 7.44 | ||||
| BGNE | BeiGene | 7.31 | ||||
| APLS | Apellis Pharmaceuticals | 4.63 | ||||
| VTYX | Ventyx Biosciences | 4.33 | ||||
| AKRO | Akero Therapeutics | 3.24 | ||||
| PCVX | Vaxcyte | 2.77 | ||||
| RARE | Ultragenyx | 1.63 | ||||
| DAWN | Day One | 1.33 | ||||
| LEGN | Legend Biotech | 1.29 | ||||
| ASND | Ascendis Pharma | 1.28 | ||||
| KNSA | Kiniksa Pharmaceuticals | 1.27 | ||||
| INCY | Incyte | 0.87 | ||||
| BPMC | Blueprint Medicines | 0.50 | ||||
| NUVL | Nuvalent | 0.48 | ||||
| MNKD | MannKind Corp | 0.46 | ||||
| ALNY | Alnylam Pharmaceuticals | 0.15 | ||||
| REPL | Replimune | 2.29 |
Additional Tools for United Stock Analysis
When running United Therapeutics' price analysis, check to measure United Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy United Therapeutics is operating at the current time. Most of United Therapeutics' value examination focuses on studying past and present price action to predict the probability of United Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move United Therapeutics' price. Additionally, you may evaluate how the addition of United Therapeutics to your portfolios can decrease your overall portfolio volatility.